SCHEMBL3093010

SCHEMBL3093010

C[C@H](NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK1 Q13464 12/20 1.00
ROCK2 O75116 10/20 1.00
PRKG1 Q13976 8/20 1.00
GSK3B P49841 8/20 1.00
CLK4 Q9HAZ1 8/20 1.00
PKN2 Q16513 7/20 1.00
GSK3A P49840 7/20 1.00
PRKCD Q05655 6/20 1.00
PRKG2 Q13237 6/20 1.00
RPS6KA5 O75582 6/20 1.00
SGK2 Q9HBY8 6/20 1.00
PRKACA P17612 6/20 1.00
PRKX P51817 6/20 1.00
RPS6KB1 P23443 5/20 1.00
CDK2 P24941 5/20 1.00
MAPK1 P28482 5/20 1.00
CDK1 P06493 4/20 1.00
CDC42BPA Q5VT25 4/20 1.00
AKT1 P31749 4/20 1.00
MAP4K4 O95819 3/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3109948 1.00 ROCK1 (1.00) ROCK1ROCK2PRKG1GSK3BCLK4
SCHEMBL1568720 0.91 ROCK2 (0.83) ROCK1ROCK2PRKG1GSK3BCLK4
SCHEMBL3104747 0.87 ROCK1 (0.78) ROCK1ROCK2PRKG1GSK3BCLK4
SCHEMBL3109564 0.87 ROCK1 (0.77) ROCK1ROCK2PRKG1GSK3BCLK4
SCHEMBL3109453 0.86 ROCK1 (0.75) ROCK1ROCK2PRKG1GSK3BCLK4
SCHEMBL3103857 0.86 ROCK1 (0.75) ROCK1ROCK2PRKG1GSK3BCLK4
SCHEMBL3109180 0.86 ROCK2 (0.75) ROCK1ROCK2PRKG1GSK3BCLK4
SCHEMBL12191130 0.85 ROCK2 (0.74) ROCK1ROCK2PRKG1GSK3BCLK4
SCHEMBL3102386 0.84 ROCK2 (0.72) ROCK1ROCK2PRKG1GSK3BCLK4
SCHEMBL3109362 0.83 ROCK1 (0.74) ROCK1ROCK2PRKG1GSK3BCLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101903349-B 4- (4-pyridinyl) -benzamides and their use as ROCK activity modulators ABBOTT GMBH & CO KG 2014-01-08 CN claimed
US-20150105386-A1 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS ABBVIE DEUTSCHLAND (DE) 2015-04-16 US disclosed
US-8895749-B2 4-(4-pyridinyl)-benzamides and their use as rock activity modulators ABBVIE INC. (US) 2014-11-25 US disclosed
CN-103896831-A 4-(4-pyridinyl)-benzamides and their use as rock activity modulators ABBVIE DEUTSCHLAND 2014-07-02 CN disclosed
US-20130310378-A1 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS ABBVIE INC. (US) 2013-11-21 US disclosed
US-8445686-B2 4-(4-pyridinyl)-benzamides and their use as rock activity modulators ABBVIE INC. (US) 2013-05-21 US disclosed
US-20100273828-A1 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2010-10-28 US disclosed
EP-2193119-A1 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS Abbott GmbH & Co. KG (DE) 2010-06-09 EP disclosed
WO-2009027392-A1 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS ABBOTT GMBH & CO. KG (DE) 2009-03-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130310378-A1 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS GABRR3, ROCK1, ROCK2 ROCK1 2/4885ROCK2 3/4885PRKG1 262/4885
US-20150105386-A1 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS GABRR3, ROCK1, ROCK2 ROCK1 2/4885ROCK2 3/4885PRKG1 259/4885
US-20100273828-A1 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS GABRR3, ROCK1, ROCK2 ROCK1 2/4885ROCK2 3/4885PRKG1 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.